Eli Lilly's Mounjaro overtakes Merck's Keytruda as world's top-selling drug

Mounjaro generated $8.7 billion for Lilly in the first quarter of 2026, outperforming Merck's Keytruda, which posted sales of $7.9 billion

Go to News Site